- Home
- RDI vs TCRX Comparison
RDI vs TCRX Comparison
Compare RDI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | TCRX |
|---|---|---|
| Founded | 1937 | 2018 |
| Country | United States | United States |
| Employees | 2005 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 49.4M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDI | TCRX |
|---|---|---|
| Price | $2.17 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 115.6K | ★ 935.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $202,988,000.00 | $10,325,000.00 |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.94 | $0.33 |
| 52 Week High | $2.41 | $2.57 |
Technical Indicators
Market Signals| Indicator | RDI | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 17.58 |
| Support Level | $1.00 | N/A |
| Resistance Level | N/A | $0.82 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 62.12 | 1.88 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.